The THINK Study Incidence of Neurotrophic Keratopathy)

Inclusion Criteria:

*Patients with the following: A diagnosis of dry eye disease Central or inferior corneal fluorescein staining defined by the Oxford Scale Reduced tear break up time (TBUT) ≤ 10 seconds.

• Able to comprehend and sign a statement of informed consent.

• Willing and able to complete all required postoperative visits.

Exclusion Criteria:

• Ocular surgery (e.g., intraocular, oculoplastic, corneal, or refractive surgicalprocedure) performed within the last 3 months or at any time in the investigator'sclinical judgment if it would interfere with the outcome measures of this study.

• Evidence of BAK or other chemical toxicity that, in the best judgment of theinvestigator, is causing reduced corneal sensitivity

• Concomitant use of daily contact lenses that, in the best judgment of theinvestigator, is causing reduced corneal sensitivity

• Clinically significant ocular trauma.

• Active ocular Herpes simplex or Herpes Zoster infection

• Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis,conjunctivitis) at the discretion of the investigator.

• Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungalinfection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelidsincluding hordeolum/stye).

• Active, systemic, or local disease condition that causes clinically significantocular surface irritation such that it could interfere with the study findings.

• Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis.

• Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis,staphylococcal blepharitis or seborrheic blepharitis)

• Eyelid abnormalities that significantly affect the lid function (e.g., entropion,ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severeptosis).

• Ocular surface abnormality that may compromise the corneal integrity (e.g., priorchemical burn, recurrent corneal erosion, map dot fingerprint dystrophy, or theeffect of any other ophthalmic medication that might in the opinion of theinvestigator compromise the ocular surface integrity).

• Participation in this trial in the same patient's fellow eye

• Patients who are under age 18, pregnant or breastfeeding, or who may become pregnantduring participation in the study.